Reduction in choroidal thickness of macular area in polypoidal choroidal vasculopathy patients after intravitreal ranibizumab therapy

Graefes Arch Clin Exp Ophthalmol. 2013 Oct;251(10):2415-20. doi: 10.1007/s00417-013-2419-z. Epub 2013 Jul 18.

Abstract

Background: To evaluate changes in retinal and choroidal thickness changes after three intravitreal ranibizumab (IVR) injections for polypoidal choroidal vasculopathy (PCV) using enhanced depth-imaging-optical coherence tomography (EDI-OCT).

Methods: In this retrospective, observational case series, EDI-OCT was used to measure changes in choroidal thickness at nine points in a lattice shape in the macula before and after introductory-stage IVR.

Results: Choroidal thickness was decreased at all nine points in the lattice shape, but was significantly decreased only at the fovea.

Conclusion: The subfoveal choroidal thickness may be reduced by introductory-stage IVR in patients with PCV. In particular, choroidal thickness at the fovea was reduced during the early stage of treatment.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Choroid / drug effects*
  • Choroid / pathology
  • Choroidal Neovascularization / diagnosis
  • Choroidal Neovascularization / drug therapy*
  • Female
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Macula Lutea
  • Male
  • Polyps / diagnosis
  • Polyps / drug therapy*
  • Ranibizumab
  • Retrospective Studies
  • Tomography, Optical Coherence

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Ranibizumab